LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Închisă

SectorSănătate

23.22 2.16

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

22.23

Maxim

23.97

Indicatori cheie
By Trading Economics
Venit	-29M -11M
Vânzări	-24M 105M
EPS	-0.09
Marjă de profit	-10.717
Angajați	354
EBITDA	-31M -8.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+52.83% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-282M 2.7B
Deschiderea anterioară	21.06
Închiderea anterioară	23.22

Sentimentul știrilor

By Acuity

14%

86%

21 / 344 Clasament în Healthcare

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 iun. 2026, 23:36 UTC

Câștiguri

Correction to Oracle Reports Higher 4Q Profit Article

10 iun. 2026, 23:19 UTC

Acțiuni populare

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 iun. 2026, 23:09 UTC

Principalele dinamici ale pieței

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 iun. 2026, 23:04 UTC

Câștiguri

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 iun. 2026, 20:44 UTC

Principalele dinamici ale pieței

Caterpillar Raises Quarterly Dividend 8%

10 iun. 2026, 23:49 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Should Take No Options Off The Table

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 iun. 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 iun. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 iun. 2026, 23:46 UTC

Achiziții, Fuziuni, Preluări

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 iun. 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 iun. 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 iun. 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 iun. 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 iun. 2026, 21:57 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:52 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:35 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:22 UTC

Câștiguri

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 iun. 2026, 20:50 UTC

Market Talk

Câștiguri

Tech, Media & Telecom Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 iun. 2026, 20:39 UTC

Market Talk

Câștiguri

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 iun. 2026, 20:34 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 20:33 UTC

Câștiguri

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Global Equities Roundup: Market Talk

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

52.83% sus

Prognoză pe 12 luni

Medie 34.83 USD 52.83%

Maxim 36 USD

Minim 34 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

21 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.